Prof. Santiago González-Moreno

Professor González-Moreno, born in Segovia, Spain on May 31 1968, is married and has 3 children. He completed his general surgery residency in Hospital Universitario “12 de Octubre” (Madrid). He continued his training in gastrointestinal surgical oncology as a clinical fellow for two years under Dr. Paul H. Sugarbaker at the Washington Cancer Institute in Washington, DC (USA), where he focused in peritoneal surface malignancy. Upon returning to Spain in 2001 he was commissioned to organize the surgical oncology practice at the newly created MD Anderson Cancer Center´s affiliation in Madrid, Spain where he has developed most of his career.

He received a PhD (cum laude) in appendiceal malignancy at University of Navarra in 2003 and was a Visiting Assistant Professor at the Department of Surgical Oncology in MD Anderson Cancer Center in Houston in 2005. He earned the European Board of Surgery Qualification in Surgical Oncology in 2004. He serves as editorial consultant and reviewer for several oncology scientific journals.
Professor González-Moreno´s areas of research interest include colorectal, appendix and gastric cancer, peritoneal malignancy and intraperitoneal chemotherapy, abdominopelvic sarcomas and education. He has lectured throughout Spain, Europe and South America on cyto-reductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis, having published articles in peer-reviewed journals, edited books and organized national and international scientific meetings on this topic.

He is among the founding members of the Spanish Peritoneal Surgical Oncology Group (GECOP). Among other commitments, he is the President of the Spanish Society of Surgical Oncology and is the Vice-president of the Spanish Federation of Oncological Societies since 2008. He joined the Executive Committee of the European Society of Surgical Oncology in 2008 and is currently President of the Society (2016-2018).

His present focus of research is in peritoneal carcinomatosis of gastric origin. 

Colorectal cancers are the third most common type of cancer and the second most common cause of death in Europe. The month of March has been chosen as “ Colorectal Cancer Awareness Month ”, to raise awareness about this disease, as detecting it as early as possible can save many lives. As a surgical oncologist, I can only say that a research-driven multidisciplinary approach is crucial to treat this type of malignancies. If surgery is the only treatment modality which has a curative potential by itself for solid tumours, inadequate cancer surgery can hinder the chances for a potentially curable patient to be rendered long-term disease-free. Doing surgery “right” is essential in the complex area of cancer management. It is not only a matter of how to perform a surgical operation, but mostly whether and when to do it, and under which circumstances. This is why “cancer surgery” has evolved into “surgical oncology”, a term which highlights the healthcare professional’s knowledge of tumour biology and other oncology treatments, as well as his/her belonging to a multidisciplinary team. Surgery applied in the oncologic field should be therefore performed by fully trained surgical specialists in cancer care, and this is even more necessary when we consider the complexity involved in learning the latest trends in colorectal cancer (CRC) surgery . Techniques such as laparoscopic and robotic surgery, as well as trans-anal excision, are now very sophisticated and ensure the same level of effectiveness of the open surgery approach. Thanks to minimally invasive surgery (MIS) , there is a clear shift from the necessity of mutilating anatomic structures, such as the anal sphincter, to their functional preservation. This new approach ensures eligible patients a shorter hospital stay, a quicker return to normal activities, and less pain following surgery. Nowadays, some healthcare specialists (e.g...